-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration Subgroup

Benzinga·07/20/2026 06:54:24
Listen to the news
  • After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 
  • 4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings